Dendreon DNDN: Provenge Prostate Cancer Drug Approved by FDA
Dendreon, DNDN, published a press release confirming the FDA approval of its product Provenge. Dendreon Corporation (DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic…
